These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 24993787)

  • 21. Parkinson-Related LRRK2 Mutation R1628P Enables Cdk5 Phosphorylation of LRRK2 and Upregulates Its Kinase Activity.
    Shu Y; Ming J; Zhang P; Wang Q; Jiao F; Tian B
    PLoS One; 2016; 11(3):e0149739. PubMed ID: 26930193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.
    Leveridge M; Collier L; Edge C; Hardwicke P; Leavens B; Ratcliffe S; Rees M; Stasi LP; Nadin A; Reith AD
    J Biomol Screen; 2016 Feb; 21(2):145-55. PubMed ID: 26403521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
    Garcia-Miralles M; Coomaraswamy J; Häbig K; Herzig MC; Funk N; Gillardon F; Maisel M; Jucker M; Gasser T; Galter D; Biskup S
    PLoS One; 2015; 10(4):e0118947. PubMed ID: 25830304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphorylation of p53 by LRRK2 induces microglial tumor necrosis factor α-mediated neurotoxicity.
    Ho DH; Seol W; Eun JH; Son IH
    Biochem Biophys Res Commun; 2017 Jan; 482(4):1088-1094. PubMed ID: 27914807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts.
    Li T; Ning B; Kong L; Dai B; He X; Thomas JM; Sawa A; Ross CA; Smith WW
    Cells; 2021 Feb; 10(2):. PubMed ID: 33672296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?
    Gillardon F
    J Neurochem; 2009 Sep; 110(5):1514-22. PubMed ID: 19545277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
    Lavalley NJ; Slone SR; Ding H; West AB; Yacoubian TA
    Hum Mol Genet; 2016 Jan; 25(1):109-22. PubMed ID: 26546614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1.
    Luerman GC; Nguyen C; Samaroo H; Loos P; Xi H; Hurtado-Lorenzo A; Needle E; Stephen Noell G; Galatsis P; Dunlop J; Geoghegan KF; Hirst WD
    J Neurochem; 2014 Feb; 128(4):561-76. PubMed ID: 24117733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.
    Lee BD; Dawson VL; Dawson TM
    Trends Pharmacol Sci; 2012 Jul; 33(7):365-73. PubMed ID: 22578536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of neuroinflammation by matrix metalloproteinase-8 inhibitor in aged normal and LRRK2 G2019S Parkinson's disease model mice challenged with lipopolysaccharide.
    Kim J; Jeong YH; Lee EJ; Park JS; Seo H; Kim HS
    Biochem Biophys Res Commun; 2017 Nov; 493(2):879-886. PubMed ID: 28958936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphorylation of LRRK2: from kinase to substrate.
    Lobbestael E; Baekelandt V; Taymans JM
    Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.
    Cho HJ; Liu G; Jin SM; Parisiadou L; Xie C; Yu J; Sun L; Ma B; Ding J; Vancraenenbroeck R; Lobbestael E; Baekelandt V; Taymans JM; He P; Troncoso JC; Shen Y; Cai H
    Hum Mol Genet; 2013 Feb; 22(3):608-20. PubMed ID: 23125283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.
    Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL
    Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
    Caesar M; Felk S; Zach S; Brønstad G; Aasly JO; Gasser T; Gillardon F
    Glia; 2014 Jul; 62(7):1075-92. PubMed ID: 24652679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders.
    Puccini JM; Marker DF; Fitzgerald T; Barbieri J; Kim CS; Miller-Rhodes P; Lu SM; Dewhurst S; Gelbard HA
    J Neurosci; 2015 Apr; 35(13):5271-83. PubMed ID: 25834052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2.
    Blanca Ramírez M; Lara Ordóñez AJ; Fdez E; Madero-Pérez J; Gonnelli A; Drouyer M; Chartier-Harlin MC; Taymans JM; Bubacco L; Greggio E; Hilfiker S
    Hum Mol Genet; 2017 Jul; 26(14):2747-2767. PubMed ID: 28453723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily.
    Stafa K; Tsika E; Moser R; Musso A; Glauser L; Jones A; Biskup S; Xiong Y; Bandopadhyay R; Dawson VL; Dawson TM; Moore DJ
    Hum Mol Genet; 2014 Apr; 23(8):2055-77. PubMed ID: 24282027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mouse models for LRRK2 Parkinson's disease.
    Xu Q; Shenoy S; Li C
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S186-9. PubMed ID: 22166430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mouse/human cross-species heterodimer of leucine-rich repeat kinase 2: possible significance in the transgenic model mouse of Parkinson's disease.
    Miyajima T; Ohta E; Kawada H; Maekawa T; Obata F
    Neurosci Lett; 2015 Feb; 588():142-6. PubMed ID: 25562633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.